SUMMARY. Clinical and experimental observations suggest that female sex hormones, and in particular estrogens, increase vascular sensitivity to catecholamines. We confirmed these conclusions by demonstrating in vitro that segments of small mesenteric arteries (190-290 fim in inside diameter) from male rats treated with 17/?-estradiol (10 jug/100 g body weight per day for 5-7 days) exhibited a 3.2-fold leftward shift in the contractile dose-response curve for norepinephrine, the concentration resulting in half maximal contraction decreasing from a control value of 8.4 X 10"' to 2.6 X 10~7 M. The molecular mechanisms which account for this increase in vascular smooth muscle catecholamine sensitivity are unknown. To evaluate directly the possibility that the effects of female sex hormones on the vascular sensitivity to catecholamines are mediated through changes in the a-adrenergic receptor, radioligand-binding studies using the a-1 subtype-selective ligand [ 3 H]-WB-4101 were performed on homogenates of mesenteric arteries in control and estrogen-treated male rats, and in control and oophorectomized female rats. Following estrogen treatment (250 jug/100 g body weight), receptor affinity in male rats was increased 1.9-fold for the antagonist [ 3 H]-WB-4101, and receptor density decreased slightly, from 102 ± 4 to 85 ± 5 fmol/mg protein. Estradiol at doses of 10 and 250 ftg/100 g body weight increased receptor affinity for the agonist (-)-epinephrine 2.8-and 5.7-fold, respectively. The lower dose of estradiol also increased receptor affinity for (-)-norepinephrine 4-fold. In female rats, the affinities for [ 3 H]-WB-4101 and (-)-epinephrine were 1.6-and 3.5-fold higher, respectively, than in age-matched males, with no difference in receptor density between the sexes. Following oophorectomy, the affinity for (-)-epinephrine in females was the same as in males. Testosterone treatment did not affect the density or affinity of receptors in females. These observations demonstrate that estrogens increase the affinity of a-adrenergic receptors in blood vessels, and provide evidence that the estrogen-induced increase in vascular sensitivity to catecholamine-induced contraction is mediated, at least in part, by these affinity changes. (Ore Res 50: [805][806][807][808][809][810][811] 1982) 
CLINICAL observations suggest that sex hormones may play a role in certain human diseases characterized by abnormal vascular tone. Thus, Raynaud's disease is far more common in females than in males (Coffman and Davies, 1975) . Migraine headaches in women are often worse during the premenstrual period, and may dramatically abate during pregnancy (Pearce, 1969) , as may essential hypertension (Finnerty, 1977) . Experimental data also indicate that sex hormones can alter the sensitivity of blood vessels for a-adrenergic agonists. Estrogen treatment of male rats results in an increased sensitivity of terminal mesenteric arterioles for a-adrenergic agonist-induced constriction (Altura, 1975) . Similarly, terminal mesenteric arterioles in female rats are more sensitive to catecholamine-induced constriction than arterioles in males rats (Altura, 1972) . These findings have led to the suggestion that estrogens may contribute to the increased catecholamine sensitivity of blood vessels in females through direct effects on the vascular aadrenergic receptor (Altura, 1975) .
Recently, radioligand-binding techniques have been used to demonstrate directly that sex hormones may regulate a-adrenergic receptors in certain nonvascular tissues. Using the radioligand [ 3 H]-dihydroergocryptine, it has been shown that estrogens increase the number of a-adrenergic receptors in rabbit myometrium (Williams and Lefkowitz, 1977; Roberts et al., 1977) , and decrease the number in rabbit platelets (Roberts et al., 1979) , without changing receptor affinity in either tissue. Although there are suggestions that estrogens can regulate a-adrenergic receptors in the uterus and in platelets, no information is available at present concerning possible effects of estrogens on the number or affinity of a-adrenergic receptors in vascular tissue.
As a general approach to the study of vascular aadrenergic receptor physiology, we have developed techniques for assaying a-adrenergic receptors, which are predominantly of the a-1 subtype, in a particulate fraction of the rat mesenteric artery, using [ 3 H]-dihydroergocryptine (Colucci et al., 1980) . More recently, we have characterized these receptors using the a-1 subtype selective ligand [ 3 H]-WB-4101 (phenoxy-3-3 H(N))-(2-(2,6,-dimethoxyphenoxyethyl)aminomethyl-l,4-benzodioxane) (Colucci et al., 1981) .
To study the influence of sex hormones on the vascular a-adrenergic receptor, we compared [ 3 H]-WB-4101 binding in rat mesenteric arteries in normal and estrogen-treated males, age-matched female controls, and testosterone-treated and oophorectomized females. In parallel with the receptor-binding studies, we evaluated the effect of estrogen treatment of male rats on the contractile dose-response curve for norepinephrine in segments of mesenteric resistance arteries (190-290 jum) from the rat, using the methods of Halpern et al. (1978) . The data indicate that estrogens increase the sensitivity of vascular smooth muscle to catecholamine-induced contraction, and that this increase may be due to enhanced vascular aadrenergic receptor affinity.
Methods

Reagents
[
3 H]-WB-4101 (specific activity = 24.4 Ci/mmol) was obtained from New England Nuclear. 17/S-Estradiol valerate and testosterone were obtained from E. R. Squibb and Sons, Inc. All other compounds used were purchased from standard chemical suppliers.
Mesenteric Artery Preparation
A membrane-rich particulate fraction of dissected mesenteric arteries from age-matched male and female SpragueDawley rats (300-350 g)(Charles River Breederies) was prepared using modifications of the methods of Wei et al. (1976) , as previously described in detail (Colucci et al., 1980 (Colucci et al., , 1981 . The particulate fraction from six to 12 mesenteric arterial arcades was resuspended in assay buffer (5 ITIM MgCl2, 50 IKM Tris-HCl, pH 7.55) to yield a final protein concentration of 1.0-2.0 mg/ml. Protein concentration was determined by the Lowry method with bovine serum albumin as standard (Lowry et al., 1951) .
[ 3 H]-WB-4101 Binding Assay
The binding assay mixture consisted of 25 jul of [ 3 H]-WB-4101, 100 jxl of mesenteric artery particulate fraction (0.10-0.20 mg of protein), and 25 jul of distilled water or (-)-epinephrine dissolved in distilled water. All assays were performed in the presence of 0.1 rriM ascorbic acid to prevent oxidation of catecholamines. Under standard assay conditions, particulate fraction protein was incubated with 0.1-3.0 nM [ 3 H]-WB-4101 for 20 minutes at 22°C. After incubation, the assay mixture was diluted with 4.5 ml of assay buffer (22°C), immediately filtered through a Whatman GF/C glass fiber filter, and washed with two additional 4.5-ml portions of assay buffer (22°C). Total time for filtration and washing averaged 15 seconds. Filters were dried overnight at room temperature and placed in 10 ml of Liquiscint (National Diagnostics) scintillation fluid for counting on a Beckman (model LSC345) 
In Vitro Mesenteric Artery Contraction
The myograph and vessel dissection technique used in this study is a modification of the one described by Halpern et al. (1978) . Briefly, a segment of the mesentery is removed approximately 10 cm distal to the pylorus. A vessel segment (approximately 1.4 mm in length and 190-290 fxm in diameter) was excised from connective and adipose tissue and mounted on two 32-/im tungsten wires. The wires were fastened to two stainless steel support blocks, one of which was mounted to a force transducer and the other to a displacement device. The internal circumference could therefore be altered while measuring force production. Vessel dissection and mounting were done in physiological saline solution (PSS) on ice and took approximately 1 hour. A vessel then was allowed to equilibrate at 37°C for about 20 minutes in EGTA-PSS (physiologic saline solution with EGTA). After equilibration, a normalized internal circumference (Li) was determined as previously described (Mulvany and Halpern, 1977) . Li is defined as 0.8 Lioo, Lioo being an estimate of the internal circumference which a relaxed vessel would have had in vivo when subjected to a transmural pressure of 100 mm Hg. The vessel was set at Li and equilibrated in PSS without EGTA for 1 hour prior to determining the dose-response curves.
Contraction experiments were performed in PSS which contained the following (mix): NaCI, 119; KCI, 4.7; CaCl 2 , 1.6; KH2PO4, 1.18; MgSO 4 , 1.17; NaHCO 3 , 24.0; and glucose, 5.5. For EGTA-PSS, CaCl2 was replacted by 1 ITIM EGTA. Solutions were gassed with 95% O 2 -5% CO 2 and warmed to 37°C. The bath pH was 7.3-7.4, the Pco 2 was 35-45 mm Hg, and the P02 was >100 mm Hg. A norepinephrine stock solution (1 X 10" 2 M) was made in PSS containing 176 mg/liter ascorbic acid, and appropriate dilutions were made just prior to use in the bath. Only one vessel was tested from each animal. Vessels were exposed to doses ranging from 2 X 10" 5 to 1 X 10~8 M norepinephrine: vessels were exposed for approximately 5 minutes to each dose, with at least 15 minutes between doses. There was no vessel response to PSS-ascorbic acid alone. The contractile responses for each vessel were normalized to the maximum tension obtained from each vessel and then fitted to the Hill equation (Hill, 1913) .
Animal Treatment Regimens
17/?-EstradioI (10 or 250 /ig/100 g body weight) or testosterone (2.5 mg/100 g) was injected subcutaneously every day for the indicated number of days, and the animals studied 18-24 hours after the last injection. The only exception to this regimen was the long-term (15-30 day) estrogen treatment group, which was injected once weekly and studied at least 1 week after the last injection. Female rats underwent oophorectomy at 2 weeks of age, were allowed to recover, and were utilized for radioligand studies at 10-12 weeks of age.
Calculations
Saturation radioligand-binding curves were analyzed by the method of Scatchard (1949) to determine the equilibrium dissociation constant (Kd) and the amount of radioligand bound at saturation (B ma j)-Inhibition of radioligand binding and contraction of isolated vascular segments by agonists were normalized to maximum inhibition or tension obtained, respectively, for each experiment, and fitted to the Hill equation (Hill, 1913) from which a straight line was generated by linear least squares regression of the data. From this line, the mean inhibitory concentration of agonists for binding experiments (IC50); or mean (EC50), 10% (EC10), and 90% (EC90) effective concentrations for contraction experiments were determined. All data were expressed as the geometric mean ± SEM, and analyzed by a non-paired ftest.
Results
In Vitro Contraction of Isolated Mesenteric Artery Segments from Control and Estrogen-Treated Male Rats
The mean (-)-norepinephrine dose-response curves for tension development in isolated segments of mesenteric arteries from five control and six estrogen-treated male rats is depicted in Figure 1 . Following pretreatment with low-dose 17/?-estradiol (10 fig/ 100 g per day, sc, for 5-7 days), the dose-response curve is shifted to the left of the control curve; at the EC50 this shift was 3.2-fold (control males, EC50 = 8.4 X 10~7 M; estrogen-treated males, EC50 = 2.6 X 10" 7 M; P <0.001). Complete data for the contraction experiments are shown in Table 1 .
Effect of Estrogen Treatment on the Vascular a-Adrenergic Receptor in Male Rats
Treatment of male rats with high-dose 17/S-estradiol (250 jug/100 g) resulted in an increase in the affinity of the mesenteric artery a-adrenergic receptor. By 18-24 hours, the IC50 for (-)-epinephrine had decreased from a control value of 12.7 ± 1.6 fiM (n = 12) to 3.4 JUM (n = 2). Animals studied after 5-9 days (n = 8) and 14-28 days (n = 5) had IQo's of 3.1 ± 0.8 and 3.3 ± 0.4 jiiM, respectively. Because no temporal progression of the effect of high-dose estradiol treatment was observed, these data were combined for statistical analysis. These effects of high dose estradiol on a-adrenergic receptor affinity for (-)-epinephrine, as well as the effects of a lower dose (10 /ig/100 g) administered for 5-7 days, are illustrated in Figure 2 and summarized in Table 2 . There is a dose-related leftward shift in the epinephrine concentration-response curve. The lower dose estrogen regimen decreased the IC50 for (-)-epinephrine 2.6-fold from 12.7 ± 1.6 to 4.6 ± 0.7 fiM, P <0.01; and the higher dose regimen decreased the IC50 for (-)-epinephrine 4-fold to 3.2 ± 0.4 JUM (P <0.001). This same regimen resulted in a 1.9-fold decrease in the K d of [
3 H]-WB-4101 from 0.95 ± 0.15 to 0.49 ± 0.04 nM (P <0.01). There also was a small, but significant (P <0.05), decrease in maximum 
. Effect of estrogen pretreatment of male rats (10 pg/100 g per day for 5-7 days) on contraction of isolated mesenteric artery segments by norepinephrine. Each curve represents the mean of experiments in five control (9) or six estrogen-treated (O) male rats. Bars indicate the mean ± SE for the EC50 value of each curve calculated as described in Methods.
FIGURE 2. Effect of treatment of male rats with two dose levels of 17 fi-estradioi on the potency of (-)-epinephrine in competing with [ 3 HJ-WB-4101 binding to mesenteric artery a-adrenergic receptors.
• , untreated males; O, low-dose estradiol (10 fig/100 g per day) 100 g per day), the IC50 for (-)-norepinephrine decreasing from 51 ± 13 to 9.3 ± 1.7 //.M, P <0.01 (Fig.  3) .
Injection of animals in two experiments with vehicle only (peanut oil) caused no change in maximum [
3 H]-WB-4101-binding capacity, or the affinities for [
3 H]-WB-4101 or (-)-epinephrine. The addition of 17/S-estradiol directly to the assay mixture in concentrations from 10~9 to 10~3 M also had no effect on (-)-epinephrine displacement curves.
Comparison of a-Adrenergic Receptor Properties in Male and Female Rats
In order to gain insight into the significance of the physiological sex hormone milieu for vascular a-ad- renergic receptor number and affinity, mesenteric arteries from age-matched males and females were compared. As shown in Figure 4 , the (-)-epinephrine concentration response curve in female rats is displaced to the left of the curve for age-matched male rats. As summarized in Table 3 , the IC50 for (-)-epinephrine in females was 4.5 ± 0.8 /IM, or 2.8-fold lower than for males (IC50 = 12.7 ± 1.6 JUM, P <0.001). Similarly, the K d for [
3 H]-WB-4101 was lower in female rats (0.58 ± 0.06 nM) than in males (0.95 ± 0.15 nM, P <0.01). There was no significant difference in maximum binding capacity between male and female rats (Table 3) . The IC50 for (-)-epinephrine in oophorectomized females was significantly higher than in control females (oophorectomized females, IC50 = 11.0 ± 1.1 /UM; control females IC50 = 4.5 ± 0.8 JUM; P <0.001), and was not different from control males 12.7 ± 1.6 JUM, P = NS) (Table 3 ; Fig. 4 ).
Effects of Testosterone on the Vascular a-Adrenergic Receptor in Female Rats
To evaluate the role of testosterone in the sexrelated differences in receptor affinity, female rats were treated with testosterone for 48 hours. No change in receptor density (91 fmol/mg protein; n = 2), or affinity for (-)-epinephrine (IC50 = 3.9 /iM; n = 2) or [
3 H]-WB-4101 (K d = 0.51 nM; n = 2) were noted in these animals.
Discussion
We have demonstrated by direct ligand-binding assay that estrogen administration increases the affinity of the vascular a-adrenergic receptor for the antagonist [
3 H]-WB-4101, and the agonists (-)-epinephrine and (-)-norepinephrine. The receptor in female rats exhibited higher affinity than the receptor in male rats, and following oophorectomy, receptor affinity in female rats was no longer different from that in male rats. There was no difference in receptor number between male and female rats, although a small reduction in receptor number was noted following highdose estrogen treatment of male rats.
These findings are consistent with physiological observations of the effect of estrogen treatment on catecholamine-induced contraction of rat mesenteric arteries in vitro and in situ. Pretreatment of male rats with 17/?-estradiol in the same dose as used in the binding studies caused a 3.2-fold leftward shift of the dose-response curve for a-adrenergic receptor-mediated contraction of isolated segments of mesenteric artery. This magnitude of increase in physiological responsiveness is very similar to the magnitude of increases in vascular a-receptor-binding affinities for (-)-epinephrine (2.8-fold) and (-)-norepinephrine (5.6-fold). The effect of estrogens on vascular physiological responsiveness to catecholamines observed in our study is similar to previous observations by Altura in the same vascular bed. Using optical techniques to evaluate the contraction of rat terminal mesenteric arterioles in situ, Altura demonstrated that 17/?-estradiol administered to male rats in the dose used in our binding studies (10 /xg/100 g) caused a rapid (18-24 hour) 2.2-fold increase in the sensitivity to (-)-epineprhine (Altura, 1975) , and that vessels in female rats were 7.5-fold more sensitive to epinephrine-induced contraction than vessels from male rats (Altura, 1972) . Thus, the effect of estrogen treatment and the sex of the animal on mesenteric artery catecholamine responsiveness and a-adrenergic receptor affinity are directionally the same and quantitatively similar.
Interestingly, the IC50 for inhibition of [ 3 H]-WB-4101 binding by norepinephrine (51 ± 13 JUM) is considerably higher than the EC50 for contraction of isolated mesenteric artery segments by norepinephrine (0.84 JUM). Even after adjustment of the radioligand-derived IC50 to a dissociation constant (Kd) by the methods of Cheng and Prusoff (1973) , the K d is 26-fold higher than the EC 5 o-There are a number of potential explanations for this difference. First, such a discrepancy is consistent with the existence of "spare receptors" in vascular smooth muscle such that the maximum physiological response is obtained by occupation of less than 100% of the receptors (Lefkowitz, 1979) . Alternately, the homogenization procedure may alter the natural milieu of the receptor so that the affinity determined in membrane preparations may not reflect in absolute terms the affinity in the intact vessel. Finally, the IC50 determined from ligand-binding data is a complex function of both the receptor (Lewald and Rodbard, 1970) (Alexander et al., 1975) and ligand (Cheng and Prusoff, 1973) concentration, and may be related to the physiological EC50 only relatively.
The data suggest that higher endogenous estrogen levels in females contribute to the differences in vascular catecholamine sensitivity and a-adrenergic receptor affinity. Although further studies will be required to clarify the role of other sex hormones or sex-related factors, in a limited number of observations we found that testosterone, when administered for 2 days, had no effect on a-adrenergic receptor density or affinity.
The mechanism(s) by which estrogen increases vas- 12.7 + 1.6 (12) 0.95 ± 0.15 (6) 102 ± 4 (6) 4.5 ± 0.8 (6) § 0.58 ± 0.06 (5) || 82 ± 11 (5) 11.0 + 1.1 (4)H All values represent mean + SE for the number of experiments indicated in parentheses. *-t, X. §-II -A s in Table 2 . \ -P < 0.001 vs. females. cular a-adrenergic receptor affinity is unknown. It is possible that synthesis of a new receptor protein is being induced. Alternatively, estrogen-induced changes in vascular smooth muscle cell membranes may alter the micro-environment and, hence, the conformation of the receptor. Effects by estrogens on such general membrane properties as transmembrane potential (Harder and Coulson, 1979 ) and sterol content (Fuller and Wilson, 1975) have been demonstrated in vascular smooth muscle. Although such changes could be brought about indirectly through general metabolic effects, the demonstration that estrogen receptors exist in vascular smooth muscle (Harder and Coulson, 1979) makes the probability of a direct cellular effect more likely.
Previous studies on the regulation of a-adrenergic receptors by estrogens have shown an increase in areceptor number in rabbit uterus (Williams and Lefkowitz, 1977; Roberts et al., 1977) , and a decrease in rabbit platelets (Roberts et al., 1979) , with no change in affinity in either case. A recent report indicates that the estrogen-induced increase in rabbit uterine areceptor number is due entirely to an increase in the subpopulation of a-2 receptors, with no change in the number of a-1 receptors (Hoffman et al., 1981) . Under the conditions of our study, it is unlikely that the change in agonist-binding affinity is due to an effect of estrogens on a-2 receptors. Although [ 3 H]-WB-4101 has been reported not to be selective for a-1 receptors in rabbit uterus (Hoffman and Lefkowitz, 1979) , the ligand identifies predominantly a-1 receptors in the rat mesenteric artery particulate fraction (Colucci et al., 1981) . Furthermore, attempts to identify a-2 adrenergic receptors in this tissue with the a-2 selective ligands [ ]-yohimbine have failed to identify a measurable density of a-2 receptors (unpublished observations). Whether this effect of estrogens on vascular smooth muscle a-1 adrenergic receptor affinity is unique remains to be determined. Interestingly, we have found recently that chemical sympathectomy, a maneuver which results in an increase in adrenergic receptor number in several systems (Lefkowitz, 1979) , also results in an increase in affinity, but not number, of vascular a-1 adrenergic receptors (Colucci et al., 1981) .
In conclusion, the observations presented in this report provide a potential explanatation for the increased vascular reactivity to catecholamines associated with states characterized by elevated estrogen levels. The molecular mechanisms accounting for the differences in receptor affinity that we have observed, and the pathophysiological implications of these differences, require further investigation.
